> **Layer 1** · Medicine & Health Sciences · `H11-PHARMACOGENOMICA`

## Purpose
The H11-PHARMACOGENOMICA agent integrates genomic data with pharmacological profiles to predict drug response, efficacy, and toxicity on an individualized basis. It bridges the gap between molecular biology and clinical therapeutics, ensuring that medical treatments are tailored to the unique genetic makeup of a patient.

## Technical Deep-Dive
H11-PHARMACOGENOMICA utilizes advanced polygenic risk scoring (PRS) algorithms and pharmacokinetic/pharmacodynamic (PK/PD) modeling. The agent processes variant call formats (VCF) and identifies single nucleotide polymorphisms (SNPs) associated with drug metabolism enzymes (e.g., CYP450 family). 

It applies Bayesian networks to infer the conditional probability of adverse drug reactions (ADRs) given a patient's genotype and concurrent medications. The core engine uses a modified version of the E-value algorithm from causal inference to assess the robustness of gene-drug interactions against unmeasured confounding.

## Architecture

### Input Contract
| Field | Type | Description |
|-------|------|-------------|
| patient_id | string | Unique identifier |
| genomic_profile | VCFPath | Path to sequence variants |
| proposed_drugs | List[Drug] | Candidate medications |
| clinical_covariates | Dict[str, float] | e.g., liver function, age, weight |

### Output Contract
| Field | Type | Description |
|-------|------|-------------|
| dosage_recommendations | List[DosageRec] | Adjusted dosage per drug |
| toxicity_risks | List[RiskProfile] | Predicted ADR probabilities |
| actionable_variants | List[Variant] | SNPs influencing the metabolic pathway |

### State Schema
Maintains a dynamic allele frequency graph and a ledger of observed gene-drug interactions updated via federated learning.

## Dependencies
### Upstream
- H11-GENOMICA: Provides the raw VCF data.
- H11-PHARMACOLOGIA: Provides baseline PK/PD parameters.
### Downstream
- H11-PRECISIONMED: Consumes personalized dosage recommendations.

## Failure Modes
- Epistatic Masking: Rare variant interactions masking known CYP phenotypes.
- Phenoconversion: Inflammatory states altering enzyme activity irrespective of genotype.
- Data Sparsity: High uncertainty in isolated populations with low reference genome representation.

## Performance Characteristics
- Latency: <500ms for standard panel matching; up to 10s for whole-genome polygenic risk scoring.
- Throughput: 10k patient profiles per hour per node.

## Research References
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines.
- PharmGKB knowledge base architecture.

## Implementation Notes
Employs PyTorch for Bayesian network inference and a bespoke graph database for managing the SNP-drug interaction topology.
